Abstract
We conducted a phase I study of 6-diazo-5-oxo-L-norleucine given iv on a twice weekly schedule. Twenty-six evaluable patients received 31 courses of the drug. Doses ranged from 100 to 500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently, and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 iv twice weekly.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Azo Compounds / administration & dosage*
-
Bone Marrow / drug effects
-
Carcinoma, Squamous Cell / drug therapy*
-
Diazooxonorleucine / administration & dosage*
-
Diazooxonorleucine / adverse effects
-
Drug Administration Schedule
-
Drug Evaluation
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Neoplasms / drug therapy*
-
Vomiting / chemically induced
Substances
-
Antineoplastic Agents
-
Azo Compounds
-
Diazooxonorleucine